CFF Industry Award for Path to a Cure (PTAC)
Supports United States biotechnology and synthetic biology teams connecting startups and industry through commercialization programs.
The Cystic Fibrosis Foundation's Industry Award for Path to a Cure (PTAC) is a venture-philanthropy funding mechanism that supports biopharmaceutical companies developing treatments aimed at the underlying cause of cystic fibrosis, specifically therapies addressing CFTR gene function, repair, or replacement. The Foundation committed an initial $500 million through 2025 under the Path to a Cure ini…
Discovery, platform development for gene delivery/editing, preclinical and/or clinical development of treatments addressing the underlying cause of CF (CFTR). Both US and international companies eligible.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline
Sign up free to see where teams trip up